Montelukast

Montelukast, the active ingredient in Montelukast, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children, helping to reduce airway inflammation and bronchospasm.

GNH USA supplies Montelukast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is indicated for conditions involving leukotriene‑mediated airway inflammation and bronchoconstriction. - Asthma: improves long‑term control of symptoms and reduces the frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity, allowing better exercise tolerance.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported during treatment. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional irritation of the throat. - Nausea: feeling of queasiness without vomiting. - Diarrhea: loose stools occurring intermittently. - Fatigue: reduced energy or feeling unusually tired.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Neuropsychiatric events: agitation, depression, or suicidal thoughts. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Hepatotoxicity: signs of liver injury such as jaundice or elevated enzymes.

Before initiating Montelukast, consider the following safety measures. - Liver function monitoring: assess hepatic status in patients with known liver disease. - Neuropsychiatric vigilance: watch for mood changes, depression, or suicidal ideation. - Caution in severe hepatic impairment: dose adjustment may be required. - Hypersensitivity: avoid use in individuals with known allergy to Montelukast or excipients. - Not for acute asthma attacks: do not replace rescue bronchodilators. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Montelukast plasma levels. - Phenobarbital or rifampin: can markedly reduce Montelukast exposure, decreasing therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential for altered anticoagulant effect; monitor INR. - Beta‑agonists (e.g., albuterol): may have additive bronchodilatory effects. - Antidepressants (e.g., fluoxetine): monitor for neuropsychiatric symptoms.